Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The positive expression of PTEN protein in the lung carcinoma tissues was significantly lower than that in the normal lung tissues (P = 0.013), while the level of miR-494 expression was negatively correlated with PTEN expression (r = -0.577, P < 0.01).
|
25861022 |
2015 |
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The effect of DNA methylation on PTEN expression was evaluated by treatment of lung cancer cell lines with 5-aza-2'-deoxycytidine (5AZA-CdR).
|
25638724 |
2015 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Loss of PTEN function has been detected frequently in different forms of cancers, such as breast, prostate and lung cancer, gastric and colon cancer, skin cancer, as well as endometrial carcinoma.
|
25773992 |
2015 |
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells.
|
24292675 |
2014 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other driver biomarkers in lung cancer (point mutations and rearrangements in specific genes including Her2, BRAF, NUT, MET, ROS1, DDR2, FGFR1, KRAS, and PTEN) might potentially provide additional information for clinical decision making.
|
24420742 |
2014 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the role of PTEN alternations and its association with outcome variables in the genesis of lung carcinoma are not understood fully.
|
24133589 |
2013 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog (PTEN) loss has been recently reported as a gefitinib resistance mechanism in lung cancer.
|
23592446 |
2013 |
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lack of expression of PTEN is a non-sufficient condition leads to lung cancer formation alone.
|
23261230 |
2013 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
|
23274758 |
2013 |
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that TOPK is a potential therapeutic target in lung cancer that promotes cell migration by modulating a PI3K/PTEN/AKT-dependent signaling pathway; they also suggest that high TOPK expression, either alone or in combination with a low level of PTEN, may serve as a prognostic marker for lung cancer.
|
21996732 |
2012 |
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, it was strongly indicated that activation of the PI3K/AKT/NFkB pathway by PTEN inactivation results in augmented invasiveness in lung cancer cells and lipid phosphatase activity of PTEN plays a key role in this process.
|
21333374 |
2011 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that NEDD4-1 plays a critical role in the development of NSCLC and provides novel insight on the mechanisms that contribute to inactivate PTEN in lung cancer.
|
20889565 |
2010 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
|
19351834 |
2009 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Three phenotypically related genetic syndromes and their lesions (LKB1, PTEN, and TSC1/2) are identified as frequently altered in lung cancer.
|
18728656 |
2008 |
Carcinoma of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
|
17912443 |
2007 |
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
|
17409929 |
2006 |
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
LOH of the PTEN/MMAC1 locus was common in each histologic type of primary lung cancer.
|
10470842 |
1999 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the role of the PTEN/MMAC1 gene in lung cancer, we screened 34 small cell lung cancer (SCLC) cell lines, 10 SCLC tumors, 13 non-small cell lung cancer (NSCLC) cell lines and 10 NSCLC tumors using Denaturing HPLC (DHPLC) and direct sequencing methods.
|
9696041 |
1998 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest that PTEN/MMAC1/TEP1 plays a role as a tumor suppressor gene in the genesis and/or progression of human lung cancer.
|
9598803 |
1998 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using single stranded conformation polymorphism (SSCP) analysis, we screened the PTEN/MMAC1 open reading frame of 53 lung cancer cell line cDNAs for point mutations and found that 3/35 SCLCs and 3/18 NSCLCs contained homozygous amino acid sequence altering mutations.
|
9794233 |
1998 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Implication of a protein-tyrosine-phosphatase in human lung cancer.
|
7981622 |
1994 |
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma.
|
2993207 |
1985 |
Carcinoma of lung
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
Carcinoma of lung
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|